LENZ Therapeutics, Inc. - Common Stock (LENZ)

San Diego, CA – September 27, 2025 – LENZ Therapeutics (NASDAQ: LENZ) is facing heightened scrutiny this week following a significant insider share sale by a major shareholder, Versant Venture Capital VI, L.P., and its affiliated entities. The coordinated disposition of over 135,000 shares, valued at more than $5.7

LENZ Therapeutics' VIZZ earns FDA approval as the first aceclidine-based eye drop to treat presbyopia, with U.S. launch expected in Q4 2025.

LENZ Therapeutics and Corxel Pharmaceuticals announced Phase 3 data for LNZ100, showing significant presbyopia improvements, supporting potential FDA approval.

Lenz Therapeutics shares hit a new 52-week high during Monday's session. The company announced the FDA accepted its new drug application.

LENZ stock results show that LENZ Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.

Advances in presbyopia treatment with LENZ Therapeutics' LNZ100. Clinically proven to enhance near-vision for up to 10 hours, it offers a promising alternative to reading glasses. Analysts predict a bright future with a Buy rating and $34 price target.

LENZ Therapeutics unveils Phase 3 CLARITY study results on aceclidine formulations, LNZ100 & LNZ101. LNZ100 demonstrates significant improvement in Presbyopia, achieving primary and key secondary endpoints without compromising distance visual acuity. LNZ100's safety profile remains favorable, paving the way for its lead candidacy, poised for mid-2024 NDA submission.